FDA Agrees to Priority Review of Opdivo for Gastric, Esophageal Cancers

FDA Agrees to Priority Review of Opdivo for Gastric, Esophageal Cancers

283818

FDA Agrees to Priority Review of Opdivo for Gastric, Esophageal Cancers

The U.S. Food and Drug Administration (FDA) has accepted for review — under priority status — two applications requesting the approval of Opdivo (nivolumab) for treating several types of gastric and esophageal cancers. Opdivo is an immune checkpoint inhibitor marketed by Bristol Myers Squibb that has been approved, both alone and in combination with other medications, to treat different types of cancers. Because the therapy works by interfering with the PD-1/PD-L1 signaling cascade, which is…

You must be logged in to read/download the full post.